- |||||||||| propranolol / Generic mfg., clozapine / Generic mfg.
PK/PD data, Retrospective data, Journal: Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients: a meta-analysis. (Pubmed Central) - Apr 19, 2024
These data provide initial evidence about the E. brasiliensis potential for treating chronic pain. The combination with propranolol could significantly increase systemic exposure and extended T1/2 of clozapine, and thus need to be considered in prescribing decisions.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Observational data, Journal, CINV: An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo (Pubmed Central) - Apr 19, 2024
Adverse events were reported in 3.88% of patients. Conclusions Oral NEPA was found to be effective in the Indian real-world setting, eliciting a >90% complete response with HEC and MEC regimens across the acute, delayed, and overall phases.
- |||||||||| Resolor (prucalopride) / J&J, Takeda
Preclinical, Journal: 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy. (Pubmed Central) - Apr 19, 2024
The goal of this study was to investigate the impact of chronic stimulation of 5-HT4R by two agonists, prucalopride and RS-67333, in PS19 mice, a model of tauopathy...Our data suggest that enhanced proteasome activity by synaptic mediated signaling leads to the enhanced turnover of tau initially within synapses where the receptors are localized, and over time, the treatment attenuated the accumulation of tau aggregation and improved cognitive functioning of the PS19 mice. Therefore, stimulation of 5-HT4R offers a promising therapy to rescue synapses from the accumulation of toxic synaptic tau, evident in the early stages of AD.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Dermatology by Dermatologists. (Pubmed Central) - Apr 19, 2024
Therefore, stimulation of 5-HT4R offers a promising therapy to rescue synapses from the accumulation of toxic synaptic tau, evident in the early stages of AD. No abstract available
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: T3STOPBPS: Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome (clinicaltrials.gov) - Apr 19, 2024
P1, N=5, Active, not recruiting,
Given that ITNS devices have been introduced relatively Recruiting --> Active, not recruiting | N=12 --> 5 | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
- |||||||||| lithium carbonate ER / Generic mfg., olanzapine / Generic mfg.
Preclinical, Journal: Vitamin D3 and zinc supplements augment the antimanic efficacy of lithium and olanzapine treatments in an animal model of mania. (Pubmed Central) - Apr 18, 2024
Mania was induced in C57BL/6 mice by administering methylphenidate (MPH) for 14 consecutive days...The VitD3/Zn/Oln, C50, and C100 treatment regimens reversed most of the behavioral and pathophysiological alterations; however, the C50 treatment regimen was the most efficient. This study emphasizes the importance of combining different antimanic medications like Li and Oln with nutraceutical supplements to increase their antimanic efficacy, reduce their adverse effects, and, ideally, improve the BD patient's quality of life.
- |||||||||| fluoxetine / Generic mfg.
Journal: Active microscopic colitis precipitated by fluoxetine. (Pubmed Central) - Apr 18, 2024
Some drugs have been described as triggers of colonic inflammation in predisposed individuals, while others may exacerbate microscopic colitis that evolves on its own. We present the case of a patient diagnosed with active microscopic colitis in relation to taking fluoxetine at high doses.
- |||||||||| Retrospective data, Review: Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis. (Pubmed Central) - Apr 18, 2024
Interestingly, commonly used synthetic drugs such as Fluoxetine, Escitalopram, Amitriptyline, Sertraline, Flupentixol and Melitracen, and Venlafaxine, not only appeared to be less effective than specific Chinese herbal medicines (Gan Mai Da Zao Decoction, Chaihu Jia Longgu Muli Decoction, Chai Hu Shu Gan San, Danzhi-Xiaoyao-San, and Xingnao Jieyu Decoction), but they were also related to substantially higher risk of adverse events...However, it underscores the necessity for larger, methodologically robust trials to further validate and refine these preliminary findings. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023452109.
- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023. (Pubmed Central) - Apr 18, 2024
At the current phase of the pandemic, nirmatrelvir/ritonavir, remdesivir, molnupiravir, sotrovimab (for patients from XBB.1.5 variant dominant settings), and convalescent plasma can be considered for the treatment of high-risk early-stage outpatients with COVID-19, while hospitalized patients with more severe disease can be treated with dexamethasone, anti cytokines including tocilizumab, sarilumab, baricitinib, and tofacitinib and antithrombotic agents including enoxaparin. Remdesivir oral analogues and ensitrelvir fumarate are promising agents for treating acute COVID-19, which are in phase trials now; however, ivermectin, fluvoxamine, and metformin were shown to be ineffective.
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Journal: Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder. (Pubmed Central) - Apr 18, 2024
Its efficacy, which is dose-dependent, along with a commendable tolerability profile, positions it as a potential leading option for initial treatment strategies. The discourse on dosage titration, particularly the strategy of initiating treatment at lower doses followed by gradual escalation, underscores the approach toward minimizing initial adverse effects while optimizing therapeutic outcomes, aligning with the principles of personalized medicine in psychiatric care.
- |||||||||| fluoxetine / Generic mfg.
Journal: Reversible Morphological Remodeling of Prefrontal and Hippocampal Serotonergic Fibers by Fluoxetine. (Pubmed Central) - Apr 18, 2024
Importantly, a 1-month washout period was sufficient to reverse morphological changes in both the medial prefrontal cortex and in the previously characterized hippocampus, as well as to normalize behavior, highlighting an intriguing relationship between axon density and an antidepressant-like effect. Overall, these results further demonstrate the bidirectional plasticity of defined serotonergic axons and provide additional insights into fluoxetine effects on the serotonergic system.
- |||||||||| chlorpromazine / Generic mfg.
Journal: Targeting GRP75 with a Chlorpromazine Derivative Inhibits Endometrial Cancer Progression Through GRP75-IP3R-Ca2+ -AMPK Axis. (Pubmed Central) - Apr 18, 2024
Mechanistically, the direct binding of JX57 to GRP75 impairs the structure of the mitochondria-associated endoplasmic reticulum membrane and disrupts the endoplasmic reticulum-mitochondrial calcium homeostasis, resulting in a mitochondrial energy crisis and AMP-activated protein kinase activation. Taken together, these findings highlight GRP75 as a potential prognostic biomarker and direct therapeutic target in endometrial cancer and suggest that the chlorpromazine derivative JX57 can potentially be a new therapeutic option for endometrial cancer.
- |||||||||| venlafaxine / Generic mfg.
PK/PD data, Journal: CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression. (Pubmed Central) - Apr 18, 2024
Specifically, compared with CYP2D6 normal metabolizers, (i) CYP2D6 ultra-rapid metabolizers had higher VEN clearance; (ii) CYP2D6 intermediate metabolizers had lower VEN clearance; (iii) CYP2D6 poor metabolizers had lower VEN clearance, higher VEN exposure, and higher active moiety exposure. Overall, our study showed that including a pharmacogenetic factor in a population PK model could increase model fit, and this improved model demonstrated how CYP2D6 metabolizer status affected VEN-related PK parameters, highlighting the importance of genetic factors in personalized medicine.
- |||||||||| lurasidone / Generic mfg.
Trial completion, Trial completion date: The Safety and Effectiveness of Latuda (clinicaltrials.gov) - Apr 18, 2024
P=N/A, N=3192, Completed,
Overall, our study showed that including a pharmacogenetic factor in a population PK model could increase model fit, and this improved model demonstrated how CYP2D6 metabolizer status affected VEN-related PK parameters, highlighting the importance of genetic factors in personalized medicine. Enrolling by invitation --> Completed | Trial completion date: Jun 2024 --> Jun 2023
- |||||||||| amitriptyline / Generic mfg.
Review, Journal: An Overview of Degradation Strategies for Amitriptyline. (Pubmed Central) - Apr 17, 2024
Connex issues such as stability-enhancing approaches through formulation and packaging considerations, regulatory guidelines, and quality control measures are also briefly noted. Specific case studies of amitriptyline degradation pathways forecast the future perspectives and challenges in this field, helping researchers and pharmaceutical manufacturers to provide guidelines for the most effective degradation pathways employed for minimal environmental impact.
- |||||||||| dihydroergotamine mesylate injection / Generic mfg., hyoscine butylbromide oral / Generic mfg.
Journal: Dihydroergotamine Increases Histamine Brain Levels and Improves Memory in a Scopolamine-Induced Amnesia Model. (Pubmed Central) - Apr 17, 2024
Additionally, the effects in memory produced by DHE were blocked by pre-treatment with pyrilamine (20 mg/kg, i.p.) administered 30 min before the training in the NOR paradigm and MWM. These findings allow us to demonstrate that DHE improves memory in a scopolamine-induced amnesia model through increasing histamine levels at the hippocampus due to its activity as an HNMT inhibitor.
- |||||||||| chlorpromazine / Generic mfg.
Journal: Chlorpromazine-Polypyrrole Drug Delivery System Tailored for Neurological Application. (Pubmed Central) - Apr 17, 2024
Due to its lower molecular mass compared to HEP, CPZ was readily integrated into the thin polymer matrix during deposition, with diffusion being unimpeded, as opposed to films with greater thickness. Finally, the resulting system exhibited the ability to release CPZ, enabling a dosing range of 10 mg to 20 mg per day, effectively covering the therapeutic concentration range.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Haytox: what is the evidence for a Botox spray for hay fever? (Pubmed Central) - Apr 17, 2024
Finally, the resulting system exhibited the ability to release CPZ, enabling a dosing range of 10 mg to 20 mg per day, effectively covering the therapeutic concentration range. No abstract available
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Adverse events: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants (clinicaltrials.gov) - Apr 17, 2024
P3, N=140, Active, not recruiting,
The results provided additional insight into the effect of tropisetron on renal aging and the underlying mechanisms, particularly through its ability to modulate SIRT1 signaling. Recruiting --> Active, not recruiting
- |||||||||| fluoxetine / Generic mfg.
Journal: Temperature-dependent toxicity of fluoxetine alters the thermal plasticity of marine diatoms. (Pubmed Central) - Apr 17, 2024
These findings emphasize the physiological impacts and ecological implications of fluoxetine on phytoplankton and underscore the significance of considering interactions between multiple environmental drivers when accessing the ecotoxicity of potential pollutants. The present study provides insights into crucial considerations for evaluating the impacts of pharmaceutical pollution on marine primary producers.
- |||||||||| nortriptyline / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (clinicaltrials.gov) - Apr 17, 2024
P2, N=223, Active, not recruiting,
Results suggest that PCS reduced with PTSD treatment in this population and are related to shift in depression and PTSD severity, further supporting that reported PCS symptoms may be better understood as non-specific symptoms. Recruiting --> Active, not recruiting | N=400 --> 223 | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> May 2024
- |||||||||| venlafaxine / Generic mfg., pilocarpine / Generic mfg., alprazolam / Generic mfg.
Journal: A relatively rare traditional Chinese medicine pattern of primary Sj (Pubmed Central) - Apr 16, 2024
Recruiting --> Active, not recruiting | N=400 --> 223 | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Oct 2024 --> May 2024 This case report demonstrates that TCHM can effectively treat Primary Sj
- |||||||||| fentanyl citrate / Generic mfg.
Review, Journal: Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review. (Pubmed Central) - Apr 16, 2024
Outside of FDA-approved medications for OUD, lofexidine, gabapentin, and suvorexant have limited evidence for augmenting opioid agonist initiation...Maintenance treatment continues to be superior to detoxification without continued management. Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances.
- |||||||||| amitriptyline / Generic mfg.
Journal: Amitriptyline at low dose for burning mouth syndrome. (Pubmed Central) - Apr 16, 2024
Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances. No abstract available
- |||||||||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei, Simcere, Dayvigo (lemborexant) / Eisai, Belsomra (suvorexant) / Merck (MSD)
Retrospective data, Review, Journal: Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. (Pubmed Central) - Apr 16, 2024
Lemborexant 2.5-5 mg, suvorexant 15-20 mg, and zolpidem 3.5 mg middle-of-the-night associated with lower impairment than zopiclone...Most FDA-approved hypnotics overlapped placebo at in-label doses, outperforming zopiclone. Repeated administration for 15 days or less reduced residual effects, warranting further research on the matter.
- |||||||||| mirtazapine / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal, Adverse events: Oral mirtazapine decreases the gastrointestinal adverse effects in cats on doxorubicin chemotherapy. (Pubmed Central) - Apr 16, 2024
Furthermore, the prevalence of episodes of vomiting during mirtazapine treatment was significantly lower than that during placebo treatment (P = 0.026). Our results demonstrate that mirtazapine can significantly increase bodyweight, appetite, and activity and reduce vomiting in cats after doxorubicin chemotherapy.
|
